Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | CA12 | O43570 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | STAT3 | P40763 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylparaben SCHEMBL2170181 | 0.86 | CA1 (0.59) | CA1CA2CA12CA9CA14 | |
| SCHEMBL11901631 | 0.86 | SLC6A2 (0.51) | CA1CA2CA12CA9CA14 | |
| SCHEMBL14661699 | 0.86 | SLC6A2 (0.51) | CA1CA2CA12CA9CA14 | |
| SCHEMBL1765701 | 0.86 | SLC6A2 (0.51) | CA1CA2CA12CA9CA14 | |
| SCHEMBL31376526 | 0.85 | CA1 (0.52) | CA1CA2CA12CA9CA14 | |
| SCHEMBL1765662 | 0.84 | NPC1 (0.50) | CA1CA2CA12CA9CA14 | |
| SCHEMBL14281202 | 0.84 | LOXL2 (0.58) | CA1CA2CA12CA9CA14 | |
| SCHEMBL2792701 | 0.84 | TDP1 (0.59) | CA1CA2CA12CA9CA14 | |
| SCHEMBL10777253 | 0.84 | LOXL2 (0.58) | CA1CA2CA12CA9CA14 | |
| SCHEMBL18910996 | 0.84 | CA1 (0.59) | CA1CA2CA12CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9586931-B2 | Triazolyl derivatives as Syk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9242984-B2 | Pyrazolyl derivatives as Syk inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-26 | — | — | US | disclosed |
| US-20150239866-A1 | TRIAZOLYL DERIVATIVES AS SYK INHIBITORS | MERCK CANADA INC. (CA) | 2015-08-27 | — | — | US | disclosed |
| US-20150191461-A1 | PYRAZOLYL DERIVATIVES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-07-09 | — | — | US | disclosed |
| CN-102442974-B | Camphor derivative compound, and production method and use thereof | WANG BINGJUN | 2014-07-23 | — | — | CN | disclosed |
| US-8609839-B2 | Camphor-derived compounds, method for manufacturing the same, and application thereof | NATIONAL TSING HUA UNIVERSITY (TW) | 2013-12-17 | — | — | US | disclosed |
| US-8609892-B2 | Glucagon receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2013-12-17 | — | — | US | disclosed |
| CN-102442974-A | Camphor derivative compound, and production method and use thereof | BINGJUN WANG | 2012-05-09 | — | — | CN | disclosed |
| US-8153634-B2 | Carbinol derivatives having cyclic linker | KOWA COMPANY, LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-20120077976-A1 | CAMPHOR-DERIVED COMPOUNDS, METHOD FOR MANUFACTURING THE SAME, AND APPLICATION THEREOF | NATIONAL TSING HUA UNIVERSITY (TW) | 2012-03-29 | — | — | US | disclosed |
| EP-1758853-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005123668-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005123668-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-12-29 | — | — | WO | disclosed |
| EP-1014962-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 2000-07-05 | — | — | EP | disclosed |
| WO-1999000121-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1999-01-07 | — | — | WO | disclosed |
| EP-0722440-A1 | PYRIMIDINYL-GLUTAMIC ACID DERIVATIVES | ELI LILLY AND COMPANY (US) | 1996-07-24 | — | — | EP | disclosed |
| EP-0722440-A4 | PYRIMIDINYL-GLUTAMIC ACID DERIVATIVES | LILLY CO ELI (US) | 1996-06-04 | — | — | EP | disclosed |
| US-5426110-A | Inhibiting dihydrofolate reductase in mammals and treating susceptible reoplasms | ELI LILLY AND COMPANY (US) | 1995-06-20 | — | — | US | disclosed |
| WO-1995009845-A1 | PYRIMIDINYL-GLUTAMIC ACID DERIVATIVES | ELI LILLY AND COMPANY (US) | 1995-04-13 | — | — | WO | disclosed |
| EP-0341551-A1 | Alkenoic acid derivatives | BAYER AG (DE) | 1989-11-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191461-A1 | PYRAZOLYL DERIVATIVES AS SYK INHIBITORS | SYK, BTK, LCK | CA1 3899/4885CA2 3340/4885CA12 4584/4885 |
| US-20120077976-A1 | CAMPHOR-DERIVED COMPOUNDS, METHOD FOR MANUFACTURING THE SAME, AND APPLICATION THEREOF | PDE10A, PDE6H, PRKAR2A | CA1 3123/4885CA2 3251/4885CA12 1778/4885 |
| US-20150239866-A1 | TRIAZOLYL DERIVATIVES AS SYK INHIBITORS | SYK, BTK, TYRO3 | CA1 3686/4885CA2 3049/4885CA12 4596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.